Showing results (81-90 of 117) with videos related to
Sort By:
Pageof 12
Clinical Genitourinary Cancer|April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell CarcinomaKathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.The Oncologist|September 8, 2018
An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell CarcinomaToni K Choueiri, M Dror Michaelson, Edwin M Posadas, et al.The New England Journal of Medicine|January 12, 2007
Sunitinib versus interferon alfa in metastatic renal-cell carcinomaRobert J Motzer, Thomas E Hutson, Piotr Tomczak, et al.The Oncologist|June 8, 2019
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid TumorsM Dror Michaelson, Shilpa Gupta, Neeraj Agarwal, et al.European Journal of Cancer (Oxford, England : 1990)|March 19, 2018
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival updateToni K Choueiri, Colin Hessel, Susan Halabi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinomaBrian I Rini, M Dror Michaelson, Jonathan E Rosenberg, et al.BJU International|December 5, 2013
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancerGuru Sonpavde, Gregory R Pond, Andrew J Armstrong, et al.The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.The Lancet. Oncology|October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialRobert J Motzer, Thomas E Hutson, Hilary Glen, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Models of care and NCCN guideline adherence in very-low-risk prostate cancerAyal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.Pageof 12